The role of cardiorenal biomarkers for risk stratification in the early follow-up after hospitalisation for acute heart failure. (September 2013)

• Record Type: Journal Article
• Authors: Tolonen, J.; Lassus, J. P. E.; Siirila-Waris, K.; Tarvasmäki, T.; Pulkki, K.; Sund, R.; Peuhkurinen, K.; Nieminen, M. S.; Harjola, V.-P.
• Is Part Of: Biomarkers. Volume 18:Number 6(2013)
• Page Start: 525
• Page End: 531
• Publication Date: 2013-09
• Subjects: Biochemical markers -- Periodicals; 610.28
• DOI: 10.3109/1354750X.2013.821522
• Languages: English
• ISSNs: 1354-750X

Abstract

<abstract> <title>Abstract</title> <p> <italic>Context</italic>: Cardiorenal biomarkers (CBs) predict outcome in acute heart failure (AHF).</p> <p> <italic>Objective</italic>: To evaluate CBs in early follow-up prognostication.</p> <p> <italic>Methods</italic>: In 124 AHF patients, levels of CystatinC, NT-proBNP and TroponinI measured five weeks from admission (W5) and relative change from day 2 (D2) were assessed for 6-month prognosis (mortality/HF hospitalization).</p> <p> <italic>Results</italic>: The combined end-point occurred in 33 patients (27%). D2-, W5-cystatin≥ median, and lack of ≥30%decrease in NT-proBNP were independent predictors of outcome. Additionally, a risk score established from W5 CBs identified patients with very high event rate.</p> <p> <italic>Conclusions</italic>: CBs at early follow-up of AHF may guide risk stratification.</p> </abstract>